Home » Authors » Kim Coghill

Articles by Kim Coghill

CoTherix Files Ventavis NDA In Pulmonary Arterial Hypertension

July 2, 2004

CoTherix Files Ventavis NDA In Pulmonary Arterial Hypertension

July 2, 2004

Cellegy Resubmits NDA For Cellegesic In Anal Fissures

July 1, 2004

Amylin, Lilly File For Approval Of Exenatide In Type II Diabetes

July 1, 2004

Amylin Pharmaceuticals Inc. and partner Eli Lilly and Co. filed a new drug application seeking approval of exenatide as a treatment for Type II diabetes. (BioWorld Today)

Amylin, Lilly File For Approval Of Exenatide In Type II Diabetes

July 1, 2004

Amylin Pharmaceuticals Inc. and partner Eli Lilly and Co. filed a new drug application seeking approval of exenatide as a treatment for Type II diabetes. (BioWorld Today)

Cellegy Resubmits NDA For Cellegesic In Anal Fissures

July 1, 2004

Decisions Regarding Follow-On Biologics To Be Made In Public

June 30, 2004

Decisions Regarding Follow-On Biologics To Be Made In Public

June 30, 2004

LSBC, University Of Louisville Join Up To Develop HPV Drugs

June 29, 2004

LSBC, University Of Louisville Join Up To Develop HPV Drugs

June 29, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 12, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.
LINC01116 has prognostic value in lung cancer, study shows
BioWorld MedTech
Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...